Q-omics provides the consensus-scored TRMT112 profile across patient tissues and cancer cell-line models. TRMT112 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TRMT112 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, TRMT112 protein abundance shows 23,719 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight HNSC, and PDAC as cancer lineages where TRMT112 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRMT112 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRMT112 survival associations across molecular data types. TRMT112 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRMT112 RNA expression–survival associations across cancer types. High TRMT112 expression shows unfavorable associations in HNSC, ACC, LIHC, KIRP and PAAD, but favorable associations in OV. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TRMT112 RNA expression.
This table summarizes TRMT112 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TRMT112. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRMT112 shows higher tumor expression in HNSC, BLCA, KIRC, COAD, KIRP and LIHC. The HNSC box plot shows higher TRMT112 RNA expression in tumor versus normal tissue (log2 FC = +1.161, t-test p < 0.001).
This table shows molecular features associated with TRMT112 in patient tissues and cancer cell lines. In patient samples, TRMT112 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, TRMT112 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
